Physical activity in long-term survivors of germ-cell cancer

European Journal of Cancer

Volumn 39, Issue 9, 2003, Pages 1191-1193

  Sleijfer, S ^a   De Wit, R ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DRUG INDUCED DISEASE; DRUG SAFETY; FATIGUE; GERM CELL TUMOR; HUMAN; LUNG FIBROSIS; MALE; MENTAL STRESS; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHYSICAL ACTIVITY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; RISK FACTOR; TESTIS CARCINOMA; TESTOSTERONE BLOOD LEVEL;

EID: 0037565380     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00269-7     Document Type: Editorial

References (14)

1. De Wit R. Treatment of disseminated non-seminomatous testicular cancer. Semin. Surg. Oncol. 17:1999;250-256.
2. De Wit R., Roberts J.T., Wilkinson P.M.et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis gem cell cancer. a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J. Clin. Oncol. 19:2001;1629-1640.
3. Xiao H., Mazumbar M., Bajorin D.F.et al. Long-term follow-up of patients with good risk germ-cell tumors treated with etoposide and cisplatin. J. Clin. Oncol. 15:1997;2553-2558.
4. Meinardi M.T., Gietema J.A., Van der Graaf W.T.et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18:2000;1725-1732.
5. Gietema J.A., Sleijfer D.T., Willemse P.H.et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Int. Med. 116:1992;709-715.
6. Nuver J., Smit A.J., Postma A.et al. The metabolic syndrome in long-term cancer survivors, an important target for secondary measures. Cancer Treat Rev. 28:2002;195-214.
7. Strumberg D., Brugge S., Korn M.W.et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol. 13:2002;229-236.
8. Demark-Wahnefried W., Peterson B.L., Winer E.P.et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 19:2001;2381-2389.
9. Thorsen L, Nystad W, Fossa SD. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 2003, 39, this issue (doi: 10.1016/SO959-8049(03)00151-5.
10. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 120:2001;617-624.
11. O'Sullivan J.M., Huddart R.A., Norman A.R.et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol. 14:2003;91-96.
12. Erikssen G., Liestol K., Bjornholt J., Thaulow E., Sandvik L., Erikssen J. Changes in physical fitness and changes in mortality. The Lancet. 352:1998;759-762.
13. Wannamethee S.G., Shaper A.G., Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. The Lancet. 351:1998;1603-1608.
14. Armstrong L. It's Not about the Bike. My Journey back to Life. 2000;G.P. Putnam's Sons, New York.